Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218746186
Browse in-depth TOC on "GLP-1 Analogues Market".
405 - Tables
59 - Figures
315 - Pages
Ozempic Leads the Charge in the GLP-1 Analogue Market
In 2023, Ozempic (semaglutide) dominated the GLP-1 Analogue market, buoyed by its significant revenue contribution and broad global application for diabetes treatment. Its market presence extends to obesity treatment under the brand Wegovy in Brazil, with a notable growth rate of approximately 70% from 2019 to 2023. Such robust performance underscores Ozempic's pivotal role in driving market expansion throughout the forecast period.
Single-Dose Formats Propel Growth in GLP-1 Analogue Adoption
The single-dose segment held the largest share of the GLP-1 Analogue market in 2023, a trend expected to persist. This dominance is attributed to the convenience and enhanced adherence facilitated by products like WEGOVY and TRULICITY, which offer comfortable weekly self-administration via autoinjectors. These advantages are set to bolster the segment's growth moving forward.
Subcutaneous Administration Commands Market Preference
In 2023, subcutaneous administration accounted for the largest market share in the GLP-1 Analogue segment, leveraging its ability to bypass gastrointestinal adverse effects and deliver rapid therapeutic effects. This preference is bolstered by the availability of diverse injector types, including pen injectors and autoinjectors, catering to varied patient needs.
Diabetes Indication Spearheads GLP-1 Analogue Market
The diabetes indication segment emerged as the largest in the GLP-1 Analogue market in 2023, driven by increasing demand for effective Type-2 Diabetes management. This growth is further supported by a robust research and development pipeline focusing on enhancing therapeutic outcomes compared to other antidiabetic drug classes.
Home Care Settings Drive GLP-1 Analogue Adoption
Home care settings dominated the GLP-1 Analogue market in 2023, facilitated by the convenience and patient adherence advantages offered by at-home drug administration. This trend is augmented by the expanding utilization of GLP-1 Analogue drugs in treating obesity outside traditional healthcare facilities.
North America Poised for Significant Growth in GLP-1 Analogue Market
North America, particularly the US, is expected to exhibit the highest growth rate in the GLP-1 Analogue market during the forecast period. This projection stems from increasing adoption of GLP-1 drugs for diabetes and obesity treatment, supported by well-established healthcare infrastructure and favorable reimbursement frameworks.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=218746186
Dominance of Novo Nordisk A/S in the GLP-1 Analogue Market
Novo Nordisk A/S (Denmark) stands as a pivotal force in the GLP-1 Analogue market, boasting a diverse product portfolio highlighted by flagship products like Ozempic and Wegovy. The company's extensive global distribution channels and robust R&D efforts underscore its leadership in insulin and GLP-1 manufacturing worldwide. Novo Nordisk's focus on developing oral formulations of existing GLP-1 drugs further enhances patient convenience and therapeutic efficacy.
Eli Lilly and Company's Strategic Expansion in GLP-1 Analogue Market
Eli Lilly and Company (US) plays a prominent role in advancing the GLP-1 Analogue market, with significant investments exceeding USD 9 billion in R&D during 2023 alone. The company's commercialized products, including Mounjaro, Trulicity, and Zepbound, contribute substantially to its revenue, with Trulicity and Mounjaro jointly accounting for approximately 36% of total earnings in 2023. Eli Lilly's ongoing focus on expanding its clinical pipeline reinforces its competitive position in the market.
Sanofi's Global Presence and Regulatory Advancements
Sanofi (France) maintains a strong foothold in the GLP-1 Analogue market through products like Soliqua, marketed in over 80 countries worldwide. The company's strategic approach includes securing regulatory approvals across diverse geographies, exemplified by recent approvals in China for Soliqua to enhance glycemic control in adults with type 2 diabetes. Sanofi's expansive geographic reach and rigorous regulatory strategies position it as a key player driving market growth and accessibility.
For more information, inquire now! Inquire Now
Related Reports:
Active Pharmaceutical Ingredient Market
Healthcare Analytical Testing Services Market
Mice Model Market
Digital Therapeutics Market
Pen Needles Market
Get access to the latest updates on GLP-1 Analogues Companies and GLP-1 Analogues Market Size
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
SOURCE MarketsandMarkets
Share this article